Practical Advances in the Diagnosis of Haemophilia and von Willebrand Disease Including Monitoring of Non‐Factor Replacement Therapies
Haemophilia · 16.04.2026
DOI: 10.1111/hae.70224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 16.04.2026. Verfasst von Annette Bowyer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Coagulation, Royal Hallamshire Hospital, Sheffield, UK. Die Arbeit nennt 94 Literaturangaben.
Abstract (Originalsprache)
Traditional haemophilia therapies act to replace the relevant missing clotting factor, are not interchangeable between haemophilia A and B and cannot be used in patients with high titre inhibitors. Novel non‐replacement factor therapies (NFT) target other endogenous coagulation proteins or anticoagulants such as antithrombin (AT) and tissue factor pathway inhibitor (TFPI) to rebalance haemostasis. As such, pharmaceutical clinical trials of these molecules have enrolled patients with haemophilia A or B, with and without inhibitors. The requirement for monitoring the efficacy of NFTs is greatly reduced compared to replacement therapy and global assays such as thrombin generation assay (TGA) have been used extensively in clinical trials to indicate improvement to haemostasis. Comprehensive haemophilia care, including access to and laboratory monitoring of replacement and NFTs, is well established in high income countries, but there are profound global inequities in the diagnosis and treatment of haemophilia which still need to be remedied. The authors examine the challenges of haemophilia and von Willebrand diagnosis and monitoring of NFTs using conventional and global assays of haemostasis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Coagulation, Royal Hallamshire Hospital, Sheffield, UK.
- Laboratory Hemostasis and Thrombosis, Hematology and Hemotherapy Center, University of Campinas UNICAMP, Campinas, São Paulo, Brazil.
- French Reference Center for Haemophilia and Clinical Haemostasis Unit, Louis Pradel Hospital, Lyon, France.
- Faculty of Medicine Lyon Est, UR4609 Research Laboratory on Haemophilia, University Claude Bernard Lyon 1, Lyon, France.
ORCID-Profile: Annette Bowyer, Silmara Montalvão, Yesim Dargaud
Zitieren
APA
Bowyer, A., Montalvão, S., & Dargaud, Y. (2026). Practical Advances in the Diagnosis of Haemophilia and von Willebrand Disease Including Monitoring of Non‐Factor Replacement Therapies. Haemophilia. https://doi.org/10.1111/hae.70224
Vancouver
Bowyer A, Montalvão S, Dargaud Y. Practical Advances in the Diagnosis of Haemophilia and von Willebrand Disease Including Monitoring of Non‐Factor Replacement Therapies. Haemophilia. 2026. doi:10.1111/hae.70224
BibTeX
@article{Bowyer2026,
author = {Bowyer, Annette and Montalvão, Silmara and Dargaud, Yesim},
title = {Practical Advances in the Diagnosis of Haemophilia and von Willebrand Disease Including Monitoring of Non‐Factor Replacement Therapies},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70224}
}
EUVIMED